Real-life Study of Switching from Ranibizumab or Aflibercept to Faricimab in Adults with Exudative Age-related Macular Degeneration

What this Trial Is About

Age-related macular degeneration AMD is a progressive eye condition affecting the retina. The introduction of anti-VEGF treatments like ranibizumab and aflibercept has improved management of the exudative form of this disease. Recently, Faricimab, a new bi-specific monoclonal antibody targeting VEGF-A and ANG2, was authorized for use, offering the potential to extend the time between injections compared to earlier treatments. This study aims to evaluate the real-life effects of switching patients from ranibizumab or aflibercept to Faricimab in those with refractory or dependent exudative AMD. Participants who have been treated with ranibizumab or aflibercept for more than one year and require injections at intervals shorter than 12 weeks will be observed after switching to Faricimab. This observational study involves monitoring patients during routine care without altering their treatment plan. The main focus is on measuring changes in the injection interval six months after starting Faricimab, comparing it to previous treatment intervals. During the study, participants will be monitored for differences in the number of weeks between injections before and after switching to Faricimab. Secondary assessments include the time to disease recurrence before and after the switch. The study duration extends up to one year, during which researchers will collect data from regular clinical visits and treatments. Participants safety and treatment response will be tracked under standard medical supervision throughout this period.

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.